Orphazyme - Biotech Riding for ALS

More information

Orphazyme is a Danish biopharmaceutical company with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases. We develop new therapies that mobilize a group of stress-response proteins, called heat-shock proteins. Heat-shock proteins help restore balance to cells affected by stress arising from misfolded proteins, protein aggregates, and lysosomal dysfunction. Our pipeline comprises three potential registration studies, with the first potential marketing authorization expected in 2020.

The ORARIALS-01 Clinical Trial is an 18 Month study of arimoclomol vs placebo in people living with ALS. The trial is being conducted in EU and North America. The patient joined the trial in July 2018 and the last began their treatment in July 2019.

Orphazyme actively collaborates with patient advocacy groups and research consortiums/networks to better understand how we can maximise our contribution to research and to listen to the needs of patients and their families.

You can create your own personalized poster to draw attention to this fundraising page. After printing the poster you can hang it in a shop, a café window or a community bulletin board. Ask your family, friends, co-workers and neighbors to help and also put up a poster in their home, school or work place. Most people are willing to help but be sure to ask permission first.



View all

Tour du ALS is the largest event organized by the ALS Netherlands Foundation. Under the slogan “Get on your feet to beat ALS” , hundreds of cyclists, runners and hikers climb the Mont Ventoux together with ALS patients. All participants, volunteers, patients, donors and attendees contribute in the steps towards finding the cause of ALS and ultimately a medicine.